JAMP TELMISARTAN-HCT: Affected lots may contain higher dosage than the labelled dose
Brand(s)
Last updated
Summary
Product
JAMP TELMISARTAN-HCT
Issue
Health products - Product quality
What to do
Consult your health care professional if you have any health concerns.
Affected products
| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot |
|---|---|---|---|---|---|
| JAMP TELMISARTAN-HCT | JAMP TELMISARTAN-HCT | DIN 02389940 | Tablet | Telmisartan 80 mg/ Hydrochlorothiazide 12.5 mg | EG22TCJ001 |
Issue
Possible presence of tablets containing only the hydrochlorothiazide layer in the affected lot which may also result in a higher dosage than the labelled dose of 12.5 mg.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
JAMP Pharma Corporation
1310 Nobel Street
Boucherville, Quebec
J4B 5H3
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type II
Identification number
RA-74945
Get notified
Receive notifications for new and updated recalls and alerts by category.